Rebecca M.  Henderson net worth and biography

Rebecca Henderson Biography and Net Worth

Director of IDEXX Laboratories
Dr. Rebecca M. Henderson Ph.D. serves as Independent Director of the Company. Dr. Henderson has been the John and Natty McArthur University Professor at Harvard University since 2011. Before joining Harvard’s faculty, from 1998 to 2009 Dr. Henderson served as the Eastman Kodak Professor of Management, Sloan School of the Massachusetts Institute of Technology. Dr. Henderson is also a research fellow at the National Bureau of Economic Research and a fellow of both the British Academy and of the American Academy of Arts and Sciences. Dr. Henderson holds an undergraduate degree from the Massachusetts Institute of Technology and a PhD in business economics from Harvard University. As a Harvard Business School professor of general management and strategy and an author of both books and articles regarding sustainability, strategy and innovation, Dr. Henderson brings substantial expertise in corporate strategy, sustainability, compensation practices, corporate responsibility and governance issues, with a particular focus on high-technology businesses. This expertise, combined with her deep knowledge of and insight into our businesses, operations and organization from her more than fifteen years of service on the Board, uniquely positions Dr. Henderson to offer valuable insights into the organizational and strategic issues faced by IDEXX.

What is Rebecca M. Henderson's net worth?

The estimated net worth of Rebecca M. Henderson is at least $7.75 million as of February 23rd, 2021. Dr. Henderson owns 17,742 shares of IDEXX Laboratories stock worth more than $7,752,899 as of September 28th. This net worth estimate does not reflect any other assets that Dr. Henderson may own. Learn More about Rebecca M. Henderson's net worth.

How do I contact Rebecca M. Henderson?

The corporate mailing address for Dr. Henderson and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on Rebecca M. Henderson's contact information.

Has Rebecca M. Henderson been buying or selling shares of IDEXX Laboratories?

Rebecca M. Henderson has not been actively trading shares of IDEXX Laboratories within the last three months. Most recently, Rebecca M. Henderson sold 3,046 shares of the business's stock in a transaction on Tuesday, February 23rd. The shares were sold at an average price of $513.41, for a transaction totalling $1,563,846.86. Following the completion of the sale, the director now directly owns 17,742 shares of the company's stock, valued at $9,108,920.22. Learn More on Rebecca M. Henderson's trading history.

Who are IDEXX Laboratories' active insiders?

IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.

Are insiders buying or selling shares of IDEXX Laboratories?

During the last year, insiders at the sold shares 13 times. They sold a total of 99,063 shares worth more than $47,201,358.58. The most recent insider tranaction occured on August, 31st when CEO Jonathan Jay Mazelsky sold 13,424 shares worth more than $6,873,222.24. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.

Information on this page was last updated on 8/31/2023.

Rebecca M. Henderson Insider Trading History at IDEXX Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2021Sell3,046$513.41$1,563,846.8617,742View SEC Filing Icon  
11/10/2020Sell5,902$435.91$2,572,740.8220,598View SEC Filing Icon  
5/13/2020Sell13,396$286.66$3,840,097.3620,670View SEC Filing Icon  
8/14/2019Sell4,000$271.17$1,084,680.0014,696View SEC Filing Icon  
5/13/2019Sell8,790$241.57$2,123,400.3027,486View SEC Filing Icon  
11/27/2018Sell3,504$194.92$682,999.6822,200View SEC Filing Icon  
8/23/2017Sell5,156$153.29$790,363.2417,274View SEC Filing Icon  
8/22/2017Sell2,578$152.86$394,073.0817,274View SEC Filing Icon  
5/4/2017Sell1,700$159.95$271,915.0021,552View SEC Filing Icon  
8/25/2016Sell9,924$110.43$1,095,907.3216,678View SEC Filing Icon  
11/12/2015Sell2,300$68.39$157,297.0021,450View SEC Filing Icon  
2/5/2015Sell2,934$156.27$458,496.18View SEC Filing Icon  
See Full Table

Rebecca M. Henderson Buying and Selling Activity at IDEXX Laboratories

This chart shows Rebecca M Henderson's buying and selling at IDEXX Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IDEXX Laboratories Company Overview

IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $436.98
Low: $434.98
High: $441.70

50 Day Range

MA: $496.05
Low: $432.42
High: $556.67

2 Week Range

Now: $436.98
Low: $317.06
High: $564.73


396,057 shs

Average Volume

451,062 shs

Market Capitalization

$36.27 billion

P/E Ratio


Dividend Yield



Holding NVDA? Read This Now
NVDA is likely not the best buy for A.I. investors. 50-year Wall Street veteran Marc Chaikin reveals what to buy instead. Learn more here.
Learn more here.